CA2154689C - Composition immunotherapeutique amelioree - Google Patents

Composition immunotherapeutique amelioree Download PDF

Info

Publication number: CA2154689C
Authority: CA; Canada
Prior art keywords: cell wall; wall fraction; composition; fraction; suspension
Prior art date: 1993-01-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA002154689A

Other languages

English (en)

Other versions

CA2154689A1 (fr

Inventor

Stanley J. Alkemade

Graeme Mcrae

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Telesta Therapeutics Inc

Original Assignee

Bioniche Life Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-29

Filing date

1994-01-28

Publication date

2007-05-01

1994-01-28 Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc

1994-01-28 Priority claimed from PCT/CA1994/000054 external-priority patent/WO1994016727A1/fr

1994-08-04 Publication of CA2154689A1 publication Critical patent/CA2154689A1/fr

2007-05-01 Application granted granted Critical

2007-05-01 Publication of CA2154689C publication Critical patent/CA2154689C/fr

2014-01-28 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 30
230000001024 immunotherapeutic effect Effects 0.000 title 1
210000002421 cell wall Anatomy 0.000 claims abstract description 127
239000000284 extract Substances 0.000 claims abstract description 50
238000002360 preparation method Methods 0.000 claims abstract description 19
210000000987 immune system Anatomy 0.000 claims abstract description 16
230000004936 stimulating effect Effects 0.000 claims abstract description 13
210000004027 cell Anatomy 0.000 claims description 44
239000007900 aqueous suspension Substances 0.000 claims description 35
230000001580 bacterial effect Effects 0.000 claims description 31
239000000725 suspension Substances 0.000 claims description 31
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
241000894006 Bacteria Species 0.000 claims description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
241000186359 Mycobacterium Species 0.000 claims description 8
239000011780 sodium chloride Substances 0.000 claims description 8
241000187481 Mycobacterium phlei Species 0.000 claims description 7
241000316848 Rhodococcus <scale insect> Species 0.000 claims description 7
229920002674 hyaluronan Polymers 0.000 claims description 7
229940055036 mycobacterium phlei Drugs 0.000 claims description 7
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
241000186216 Corynebacterium Species 0.000 claims description 6
229920002683 Glycosaminoglycan Polymers 0.000 claims description 6
229960003160 hyaluronic acid Drugs 0.000 claims description 6
230000001954 sterilising effect Effects 0.000 claims description 6
241000588807 Bordetella Species 0.000 claims description 5
241000037164 Collema parvum Species 0.000 claims description 5
239000007864 aqueous solution Substances 0.000 claims description 5
238000004659 sterilization and disinfection Methods 0.000 claims description 5
241000186031 Corynebacteriaceae Species 0.000 claims description 4
241000186394 Eubacterium Species 0.000 claims description 4
241000186779 Listeria monocytogenes Species 0.000 claims description 4
241000187654 Nocardia Species 0.000 claims description 4
208000020154 Acnes Diseases 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
239000003755 preservative agent Substances 0.000 claims description 2
230000002335 preservative effect Effects 0.000 claims description 2
150000002632 lipids Chemical class 0.000 claims 7
239000012634 fragment Substances 0.000 claims 2
102000004169 proteins and genes Human genes 0.000 claims 2
241001465754 Metazoa Species 0.000 abstract description 23
206010028980 Neoplasm Diseases 0.000 abstract description 23
208000015181 infectious disease Diseases 0.000 abstract description 8
241000282412 Homo Species 0.000 abstract description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
201000010099 disease Diseases 0.000 abstract description 2
239000002955 immunomodulating agent Substances 0.000 abstract description 2
239000003921 oil Substances 0.000 description 34
239000008188 pellet Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
238000005119 centrifugation Methods 0.000 description 11
230000000694 effects Effects 0.000 description 11
210000000952 spleen Anatomy 0.000 description 10
108090000631 Trypsin Proteins 0.000 description 9
102000004142 Trypsin Human genes 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000007924 injection Substances 0.000 description 9
239000012588 trypsin Substances 0.000 description 9
108091005804 Peptidases Proteins 0.000 description 7
102000035195 Peptidases Human genes 0.000 description 7
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
239000002671 adjuvant Substances 0.000 description 6
230000003308 immunostimulating effect Effects 0.000 description 6
239000000463 material Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000011282 treatment Methods 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
210000002540 macrophage Anatomy 0.000 description 5
241000894007 species Species 0.000 description 5
239000008223 sterile water Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 5
229940033663 thimerosal Drugs 0.000 description 5
108010059712 Pronase Proteins 0.000 description 4
230000037396 body weight Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
239000004202 carbamide Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000012530 fluid Substances 0.000 description 4
229960001438 immunostimulant agent Drugs 0.000 description 4
239000003022 immunostimulating agent Substances 0.000 description 4
244000005700 microbiome Species 0.000 description 4
238000002156 mixing Methods 0.000 description 4
230000008569 process Effects 0.000 description 4
239000000047 product Substances 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
102000013967 Monokines Human genes 0.000 description 3
108010050619 Monokines Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000003599 detergent Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
238000009169 immunotherapy Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 2
208000007433 Lymphatic Metastasis Diseases 0.000 description 2
206010057249 Phagocytosis Diseases 0.000 description 2
241000194017 Streptococcus Species 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
229960001614 levamisole Drugs 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000003760 magnetic stirring Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
230000008782 phagocytosis Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
239000013049 sediment Substances 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 2
229960001005 tuberculin Drugs 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
208000030507 AIDS Diseases 0.000 description 1
238000012371 Aseptic Filling Methods 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000595586 Coryne Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
241000282324 Felis Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000007514 Herpes zoster Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
102000000589 Interleukin-1 Human genes 0.000 description 1
HACHPVCYFLSKSB-UMJDSZQGSA-N ManNAz-DBCO-Pam3CSK4 Chemical compound CCCCCCCCCCCCCCCC(N[C@H](CSCC(COC(CCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCC)=O)C(N[C@H](CO)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(N[C@H](CCCCN)C(NCCC(N(C1)C2=CC=CC=C2C2N(C(N[C@H]([C@H](C3)O)[C@H]([C@@H]([C@@H](CO)O)O)O[C@@]3(C(O)=O)O)=O)N=NC2C2=C1C=CC=C2)=O)=O)=O)=O)=O)=O)=O)=O HACHPVCYFLSKSB-UMJDSZQGSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
206010027459 Metastases to lymph nodes Diseases 0.000 description 1
206010073734 Microembolism Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000169439 Nocar Species 0.000 description 1
208000008071 Parvoviridae Infections Diseases 0.000 description 1
241000577218 Phenes Species 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
206010051497 Rhinotracheitis Diseases 0.000 description 1
241000219289 Silene Species 0.000 description 1
206010040943 Skin Ulcer Diseases 0.000 description 1
229920002385 Sodium hyaluronate Polymers 0.000 description 1
206010041660 Splenomegaly Diseases 0.000 description 1
241000187392 Streptomyces griseus Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229940095564 anhydrous calcium sulfate Drugs 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000008366 buffered solution Substances 0.000 description 1
230000000981 bystander Effects 0.000 description 1
239000011575 calcium Substances 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
230000008162 cell wall modification Effects 0.000 description 1
229940047120 colony stimulating factors Drugs 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000013078 crystal Substances 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000006837 decompression Effects 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003544 deproteinization Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
230000009429 distress Effects 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
HXQVQGWHFRNKMS-UHFFFAOYSA-L ethylmercurithiosalicylate Chemical compound CC[Hg]SC1=CC=CC=C1C([O-])=O HXQVQGWHFRNKMS-UHFFFAOYSA-L 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006058 immune tolerance Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000005562 infectious bovine rhinotracheitis Diseases 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000035987 intoxication Effects 0.000 description 1
231100000566 intoxication Toxicity 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
208000037819 metastatic cancer Diseases 0.000 description 1
208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000009928 pasteurization Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
229920000056 polyoxyethylene ether Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
208000012802 recumbency Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000979 retarding effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000011218 seed culture Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229940010747 sodium hyaluronate Drugs 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000010414 supernatant solution Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229940030325 tumor cell vaccine Drugs 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
230000002476 tumorcidal effect Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
239000007762 w/o emulsion Substances 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002154689A 1993-01-29 1994-01-28 Composition immunotherapeutique amelioree Expired - Lifetime CA2154689C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1165593A	1993-01-29	1993-01-29
US011,655		1993-01-29
PCT/CA1994/000054 WO1994016727A1 (fr)	1993-01-29	1994-01-28	Composition immunotherapeutique

Publications (2)

Publication Number	Publication Date
CA2154689A1 CA2154689A1 (fr)	1994-08-04
CA2154689C true CA2154689C (fr)	2007-05-01

Family

ID=38051317

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002154689A Expired - Lifetime CA2154689C (fr)	1993-01-29	1994-01-28	Composition immunotherapeutique amelioree

Country Status (1)

Country	Link
CA (1)	CA2154689C (fr)

1994
- 1994-01-28 CA CA002154689A patent/CA2154689C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2154689A1 (fr)	1994-08-04

Legal Events

Date	Code	Title	Description
2001-01-24	EEER	Examination request
2014-04-01	MKEX	Expiry	Effective date: 20140128

Publication	Publication Date	Title
US5759554A (en)	1998-06-02	Immunostimulatory bacterial cell wall traction
US4744984A (en)	1988-05-17	Antiviral immunotherapeutic agent and preparation thereof
Rice et al.	2007	Mannheimia haemolytica and bovine respiratory disease
Yuki et al.	2003	New generation of mucosal adjuvants for the induction of protective immunity
US20120014991A1 (en)	2012-01-19	Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
JPH06501478A (ja)	1994-02-17	ブドウ膜炎の処置
CN102238960B (zh)	2014-04-23	制造疫苗的方法
CN1602199B (zh)	2012-04-04	用于治疗包含免疫失调的疾病的革兰氏阳性菌制剂
CA2154689C (fr)	2007-05-01	Composition immunotherapeutique amelioree
PL201804B1 (pl)	2009-05-29	Zastosowanie szczepów Lactobacillus
US6503512B1 (en)	2003-01-07	Anti-AIDS immunomodulator complex
US4465665A (en)	1984-08-14	Detoxified E. coli neurotoxin, preparation thereof and immunological preparations containing it
Marcatili et al.	2000	Role of Pasteurella multocida, Pasteurella haemolytica and Salmonella typhimurium porins on inducible nitric oxide release by murine macrophages
RU2080875C1 (ru)	1997-06-10	Способ получения поливалентной вакцины против кишечных инфекций
RU2752140C2 (ru)	2021-07-23	Средство и способ повышения качества жизни млекопитающих
FR2652266A1 (fr)	1991-03-29	Vaccin protecteur contre l'hemophilose porcine.
TW201718006A (zh)	2017-06-01	水生物種中增強之免疫反應
KR20050001480A (ko)	2005-01-07	돈단독 예방용 백신과 이를 이용한 혼합백신